



Stereochemistry abstracts

María Ruiz,\* Vicente Ojea, Tania M. Ruanova and José M. Quintela

*Tetrahedron: Asymmetry* 13 (2002) 795



(3S,6R,1'R,2'R,3'S)-3-[4-Benzylxy-1-hydroxy-2,3-isopropylidenedioxybutyl]-2,5-diethoxy-3,6-dihydro-6-isopropylpyrazine


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +37.9 (*c* 1.9, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: asymmetric aldol reaction

Absolute configuration: 3S,6R,1'R,2'R,3'S

María Ruiz,\* Vicente Ojea, Tania M. Ruanova and José M. Quintela

*Tetrahedron: Asymmetry* 13 (2002) 795



(3S,6R,1'S,2'R,3'S)-3-[4-Benzylxy-1-hydroxy-2,3-isopropylidenedioxybutyl]-2,5-diethoxy-3,6-dihydro-6-isopropylpyrazine



[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +5.7 (*c* 2.4, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: asymmetric aldol reaction

Absolute configuration: 3S,6R,1'S,2'R,3'S

María Ruiz,\* Vicente Ojea, Tania M. Ruanova and José M. Quintela

*Tetrahedron: Asymmetry* 13 (2002) 795



(3R,6R,1'R,2'R,3'S)-3-[1,4-Dihydroxy-2,3-isopropylidenedioxybutyl]-2,5-diethoxy-3,6-dihydro-6-isopropylpyrazine



[ $\alpha$ ]<sub>D</sub><sup>21</sup> = -30.2 (*c* 2.2, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: asymmetric aldol reaction

Absolute configuration: 3R,6R,1'R,2'R,3'S

María Ruiz,\* Vicente Ojea, Tania M. Ruanova and José M. Quintela

*Tetrahedron: Asymmetry* 13 (2002) 795





(3S,6R,1'R,2'R,3'S)-3-[1,4-Dihydroxy-2,3-isopropylidenedioxybutyl]-2,5-diethoxy-3,6-dihydro-6-isopropylpyrazine


[ $\alpha$ ]<sub>D</sub><sup>26</sup> = +38.0 (*c* 1.6, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: asymmetric aldol reaction


Absolute configuration: 3S,6R,1'R,2'R,3'S

(4*R*,5*R*,6*R*,5'*R*,2'S)-6-(3,6-Diethoxy-5-isopropyl-2,5-dihydro-pyrazin-2-yl)-2,2-dimethyl-tetrahydrofuro[3,4-*d*][1,3]dioxol-4-ol
 $[\alpha]_D^{25} = -18.6$  (final, *c* 1.2, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: asymmetric aldol reaction

Absolute configuration: 4*R*,5*R*,6*R*,5'*R*,2'SEthyl (2*S*,3*R*,4*S*,5*S*)-3-Hydroxy-4,5-isopropylidenedioxypipecolate
 $[\alpha]_D^{26} = +34.4$  (*c* 0.7, MeOH)


Source of chirality: asymmetric aldol reaction

Absolute configuration: 2*S*,3*R*,4*S*,5*S*

1-Deoxy-D-allonojirimycin

 $[\alpha]_D^{26} = +30.5$  (*c* 1.0, H<sub>2</sub>O)

Source of chirality: asymmetric aldol reaction

Absolute configuration: 2*S*,3*S*,4*R*,5*R*

1-Deoxy-D-gulonojirimycin


 $[\alpha]_D^{25} = -13.9$  (*c* 0.3, EtOH)

Source of chirality: asymmetric aldol reaction

Absolute configuration: 2*S*,3*S*,4*S*,5*R*

Yong Hyun Choi, Jun Young Choi, Hye Yon Yang  
and Yong Hae Kim\*

Tetrahedron: Asymmetry 13 (2002) 801



O,O-(R)-(1,1'-binaphthyl-2,2'-diyl)-4-(R,R-2,5-diphenylpyrrolidine)-(R)-dinaphthodioxaphosphephine



Ee >99.8%

[ $\alpha$ ]<sub>D</sub> = +556.2 (*c* 1.0, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis and (R)-1,1'-binaphthalenyl-2,2'-diol

Itaru Sato, Ryo Kodaka, Kenji Hosoi and Kenso Soai\*

Tetrahedron: Asymmetry 13 (2002) 805



1,2-Di{[4-{N-(1'S,2'R)-2'-hydroxy-1'-methyl-2'-phenylethyl-N-methyl}aminomethylphenyl]dimethylsilyl}ethane



[ $\alpha$ ]<sub>D</sub><sup>25</sup> -36.9 (*c* 1.00, CHCl<sub>3</sub>)

Source of chirality: (1R,2S)-ephedrine as starting material

Absolute configuration: 1'S,2'R

Itaru Sato, Ryo Kodaka, Kenji Hosoi and Kenso Soai\*

Tetrahedron: Asymmetry 13 (2002) 805



Tetra{3-[4-{N-(1'S,2'R)-2'-hydroxy-1'-methyl-2'-phenylethyl-N-methyl}aminomethylphenyl]dimethylsilyl}propyl silane


[ $\alpha$ ]<sub>D</sub><sup>25</sup> -26.8 (*c* 1.00, CHCl<sub>3</sub>)

Source of chirality: (1R,2S)-ephedrine as starting material

Absolute configuration: 1'S,2'R

Itaru Sato, Ryo Kodaka, Kenji Hosoi and Kenso Soai\*

Tetrahedron: Asymmetry 13 (2002) 805




Tetra{3-[tri{3-[4-{N-(1'S,2'R)-2'-hydroxy-1'-methyl-2'-phenylethyl-N-methyl}aminomethylphenyl]dimethylsilyl}propyl}silyl}propyl silane

[ $\alpha$ ]<sub>D</sub><sup>22</sup> -21.5 (*c* 1.00, CHCl<sub>3</sub>)

Source of chirality: (1R,2S)-ephedrine as starting material

Absolute configuration: 1'S,2'R




C<sub>28</sub>H<sub>28</sub>NOP

(1*R*,2*S*)-*N,N*-Dimethyl-*O*-diphenylphosphino-1,2-diphenyl-2-aminoethanol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -14.5 (*c* = 0.2, CHCl<sub>3</sub>)

Source of chirality: (1*R*,2*S*)-1,2-diphenyl-2-aminoethanol

Absolute configuration: 1*R*,2*S*




C<sub>29</sub>H<sub>30</sub>NOP

(1*R*,2*S*)-*N*-Ethyl-*N*-methyl-*O*-diphenylphosphino-1,2-diphenyl-2-aminoethanol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +38.7 (*c* = 0.7, CHCl<sub>3</sub>)

Source of chirality: (1*R*,2*S*)-1,2-diphenyl-2-aminoethanol

Absolute configuration: 1*R*,2*S*




C<sub>30</sub>H<sub>32</sub>NOP

(1*R*,2*S*)-*N*-(2-Propyl)-*N*-methyl-*O*-diphenylphosphino-1,2-diphenyl-2-aminoethanol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -39.2 (*c* = 0.36, CHCl<sub>3</sub>)

Source of chirality: (1*R*,2*S*)-1,2-diphenyl-2-aminoethanol

Absolute configuration: 1*R*,2*S*




C<sub>35</sub>H<sub>34</sub>NOP

(1*R*,2*S*)-*N*-Benzyl-*N*-methyl-*O*-diphenylphosphino-1,2-diphenyl-2-aminoethanol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +3.0 (*c* = 3.1, CHCl<sub>3</sub>)

Source of chirality: (1*R*,2*S*)-1,2-diphenyl-2-aminoethanol

Absolute configuration: 1*R*,2*S*




C<sub>35</sub>H<sub>34</sub>NOP

(1S,2S)-N-Benzyl-N-methyl-O-diphenylphosphino-1,2-diphenyl-2-aminoethanol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -24.9 (*c* = 0.86, CHCl<sub>3</sub>)

Source of chirality: (1*R*,2*S*)-1,2-diphenyl-2-aminoethanol

Absolute configuration: 1*S*,2*S*




C<sub>34</sub>H<sub>32</sub>NOP

(1*R*,2*S*)-N-Benzyl-O-diphenylphosphino-1,2-diphenyl-2-aminoethanol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -20.7 (*c* = 3.8, CHCl<sub>3</sub>)

Source of chirality: (1*R*,2*S*)-1,2-diphenyl-2-aminoethanol

Absolute configuration: 1*R*,2*S*




C<sub>30</sub>H<sub>32</sub>NOP

(1*R*,2*S*)-N-Butyl-O-diphenylphosphino-1,2-diphenyl-2-aminoethanol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -37.0 (*c* = 1.94, CHCl<sub>3</sub>)

Source of chirality: (1*R*,2*S*)-1,2-diphenyl-2-aminoethanol

Absolute configuration: 1*R*,2*S*




C<sub>29</sub>H<sub>30</sub>NOP

(1*R*,2*S*)-N-(2-Propyl)-O-diphenylphosphino-1,2-diphenyl-2-aminoethanol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -13.9 (*c* = 0.6, CHCl<sub>3</sub>)

Source of chirality: (1*R*,2*S*)-1,2-diphenyl-2-aminoethanol

Absolute configuration: 1*R*,2*S*




$C_{10}H_{12}O_2$   
(1*R*)-1-Phenylethyl acetate

E.e. >99.0% [by chiral HPLC]

$[\alpha]_D^{25} = +86.7$  (*c* 1.5,  $CHCl_3$ )

Source of chirality: enzymatic acetylation

Absolute configuration: *R*




$C_{11}H_{14}O_2$   
(1*R*)-1-Phenylpropyl acetate

E.e. >99.0% [by chiral HPLC]

$[\alpha]_D^{25} = +104.7$  (*c* 1.7,  $CHCl_3$ )

Source of chirality: enzymatic acetylation

Absolute configuration: *R*




$C_{10}H_{11}ClO_2$   
(1*S*)-2-Chloro-1-phenylethyl acetate

E.e. >99.0% [by chiral HPLC]

$[\alpha]_D^{25} = +76.6$  (*c* 1.1,  $CHCl_3$ )

Source of chirality: enzymatic acetylation

Absolute configuration: *S*




$C_{17}H_{18}O_3$   
(1*R*)-1-(4-Benzylxyphenyl)ethyl acetate

E.e. = 98.0% [by chiral HPLC]

$[\alpha]_D^{25} = +89.8$  (*c* 1.4,  $CHCl_3$ )

Source of chirality: enzymatic acetylation

Absolute configuration: *R*




$C_{13}H_{16}O_3$   
(1*R*)-1-(4-Allyloxyphenyl)ethyl acetate

E.e. >99% [by chiral HPLC]

$[\alpha]_D^{25} = +116.5$  (*c* 1.2, CHCl<sub>3</sub>)

Source of chirality: enzymatic acetylation

Absolute configuration: *R*




$C_{10}H_{11}NO_4$   
(1*R*)-1-(4-Nitrophenyl)ethyl acetate

E.e. >99% [by chiral HPLC]

$[\alpha]_D^{25} = +99.2$  (*c* 1.4, CHCl<sub>3</sub>)

Source of chirality: enzymatic acetylation

Absolute configuration: *R*




$C_{11}H_{14}O_3$   
(1*R*)-1-(4-Methoxyphenyl)ethyl acetate

E.e. = 98% [by chiral HPLC]

$[\alpha]_D^{25} = +134.7$  (*c* 1.4, CHCl<sub>3</sub>)

Source of chirality: enzymatic acetylation

Absolute configuration: *R*




$C_{14}H_{14}O_2$   
(1*R*)-1-(1-Naphthyl)ethyl acetate

E.e. >99% [by chiral HPLC]

$[\alpha]_D^{25} = +52.7$  (*c* 1.4, CHCl<sub>3</sub>)

Source of chirality: enzymatic acetylation

Absolute configuration: *R*




C<sub>13</sub>H<sub>21</sub>NO  
(1*R*,4*R*)-3-[(*E*)-(Dimethylamino)methylidene]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +484.8 (*c* 0.506, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: natural (1*R*)-(+)-camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*E*,4*R*




C<sub>21</sub>H<sub>24</sub>N<sub>4</sub>O  
(1*R*,3*R*,4*R*)-3-[(6-Phenylpyridazin-3-yl)hydrazonomethyl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 78%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -39.3 (*c* 0.293, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: natural (1*R*)-(+)-camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*




C<sub>15</sub>H<sub>19</sub>ClN<sub>4</sub>O  
(1*R*,3*R*,4*R*)-3-[(6-Chloropyridazin-3-yl)hydrazonomethyl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 22%

[ $\alpha$ ]<sub>D</sub><sup>23</sup> = -9.3 (*c* 0.484, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: natural (1*R*)-(+)-camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*




C<sub>16</sub>H<sub>19</sub>N<sub>5</sub>O  
(1*R*,3*R*,4*R*)-3-[1,2,4-Triazolo[4,3-a]pyridin-3-yl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 98%

[ $\alpha$ ]<sub>D</sub><sup>26</sup> = -9.5 (*c* 0.474, CHCl<sub>3</sub>)

Source of chirality: natural (1*R*)-(+)-camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*




C<sub>21</sub>H<sub>22</sub>N<sub>4</sub>O  
(1*R*,3*R*,4*R*)-3-[6-Phenyl-1,2,4-triazolo[4,3-*b*]pyridazin-3-yl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 92%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +107.5 (*c* 0.400, CHCl<sub>3</sub>)

Source of chirality: natural (1*R*)-(+)camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*




C<sub>15</sub>H<sub>17</sub>ClN<sub>4</sub>O  
(1*R*,3*R*,4*R*)-3-[6-Chloro-1,2,4-triazolo[4,3-*b*]pyridazin-3-yl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +97.0 (*c* 0.400, CHCl<sub>3</sub>)

Source of chirality: natural (1*R*)-(+)camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*




C<sub>19</sub>H<sub>20</sub>N<sub>4</sub>O  
(1*R*,3*R*,4*R*)-3-[1,2,4-Triazolo[4,3-*b*]phthalazin-3-yl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 100%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +66.0 (*c* 0.444, CHCl<sub>3</sub>)

Source of chirality: natural (1*R*)-(+)camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*



C<sub>15</sub>H<sub>18</sub>N<sub>4</sub>O  
(1*R*,3*R*,4*R*)-3-[1,2,4-Triazolo[4,3-*a*]pyrimidin-3-yl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -147.6 (*c* 0.245, CHCl<sub>3</sub>)

Source of chirality: natural (1*R*)-(+)camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*

Uroš Grošelj, Simon Rečnik, Jurij Svetec,\* Anton Meden and Branko Stanovnik

*Tetrahedron: Asymmetry* 13 (2002) 821



C<sub>15</sub>H<sub>18</sub>N<sub>4</sub>O

(1*R*,3*R*,4*R*)-3-[1,2,4-Triazolo[4,3-*a*]pyrazin-3-yl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -83.0 (*c* 0.336, CHCl<sub>3</sub>)

Source of chirality: natural (1*R*)-(+)camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*

Uroš Grošelj, Simon Rečnik, Jurij Svetec,\* Anton Meden and Branko Stanovnik

*Tetrahedron: Asymmetry* 13 (2002) 821



C<sub>15</sub>H<sub>17</sub>ClN<sub>4</sub>O

(1*R*,3*R*,4*R*)-3-[5-Chloro-1,2,4-triazolo[4,3-*a*]pyrazin-3-yl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 100%


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +237.0 (*c* 0.430, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: natural (1*R*)-(+)camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*

Uroš Grošelj, Simon Rečnik, Jurij Svetec,\* Anton Meden and Branko Stanovnik

*Tetrahedron: Asymmetry* 13 (2002) 821



C<sub>15</sub>H<sub>18</sub>N<sub>4</sub>O

(1*R*,3*R*,4*R*)-3-[1,2,4-Triazolo[1,5-*a*]pyrimidin-2-yl]-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one

D.e. = 92%


[ $\alpha$ ]<sub>D</sub><sup>21</sup> = +103.9 (*c* 0.440, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: natural (1*R*)-(+)camphor and stereoselective synthesis

Absolute configuration: 1*R*,3*R*,4*R*

Erik Hedenström,\* Ba-Vu Nguyen and Louis A. Silks, III

*Tetrahedron: Asymmetry* 13 (2002) 835



C<sub>11</sub>H<sub>24</sub>


(*R*)-5-Methyldecane

E.e. = 64% by specific rotation value


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -0.25 (*c* 4.5, EtOH)

Source of chirality: CRL-catalysed esterification


Absolute configuration: *R*




E.e.=87.3% by  $^{77}\text{Se}$  NMR of the corresponding (*S*)-4-isopropyl-oxazolidine-2-selone amide  
 $[\alpha]_D^{25}=+4.9$  (*c* 1.42,  $\text{CHCl}_3$ )  
Source of chirality: CRL-catalysed esterification  
Absolute configuration: *R*




E.e.=95.2% by  $^{77}\text{Se}$  NMR of the corresponding (*S*)-4-isopropyl-oxazolidine-2-selone amide  
 $[\alpha]_D^{25}=+0.2$  (*c* 1.12,  $\text{CHCl}_3$ )  
Source of chirality: CRL-catalysed esterification  
Absolute configuration: *S*



E.e.=56% by specific rotation value  
 $[\alpha]_D^{25}=+0.78$  (*c* 6.46,  $\text{CH}_2\text{Cl}_2$ )  
Source of chirality: CRL-catalysed esterification  
Absolute configuration: *S*



E.e.=83% by specific rotation value of the corresponding *R*-5-methyldecane  
 $[\alpha]_D^{25}=-1.0$  (*c* 3.84,  $\text{CHCl}_3$ )  
Source of chirality: CRL-catalysed esterification  
Absolute configuration: *R*

 $C_{11}H_{22}O_2$ 


(R)-6-Methyldecanoic acid

E.e.=41.5% by  $^{77}\text{Se}$  NMR of the corresponding (*S*)-4-isopropyl-oxazolidine-2-selone amide

$[\alpha]_D^{25}=-0.7$  (*c* 1.26,  $\text{CHCl}_3$ )

Source of chirality: CRL-catalysed esterification

Absolute configuration: *R*

 $C_{11}H_{22}O_2$ 


(R)-5-Methyldecanoic acid

E.e.=96.0% by  $^{77}\text{Se}$  NMR of the corresponding (*S*)-4-isopropyl-oxazolidine-2-selone amide

$[\alpha]_D^{25}=-0.13$  (*c* 1.51,  $\text{CHCl}_3$ )

Source of chirality: CRL-catalysed esterification

Absolute configuration: *R*

 $C_{11}H_{24}O$ 


(R)-4-Methyl-1-decanol

E.e.=63% by  $^{77}\text{Se}$  NMR of the corresponding (*S*)-4-isopropyl-oxazolidine-2-selone amide

$[\alpha]_D^{25}=+0.69$  (*c* 3.5,  $\text{CHCl}_3$ )

Source of chirality: CRL-catalysed esterification

Absolute configuration: *R*

 $C_{11}H_{22}O_2$ 


(S)-8-Methyldecanoic acid

E.e.=87% by specific rotation value

$[\alpha]_D^{25}=+6.1$  (*c* 1.14,  $\text{CHCl}_3$ )

Source of chirality: CRL-catalysed esterification


Absolute configuration: *S*

Diethyl (1*R*,2*R*)-1-benzyloxy-2,3-epoxypropylphosphonate

E.e. = 100%

 $[\alpha]_D = +20.7$  (*c* 1.23, chloroform)


Source of chirality: D-mannitol

Absolute configuration: 1*R*,2*R*Diethyl (1*S*,2*R*)-1-benzyloxy-2,3-epoxypropylphosphonate

E.e. = 100%

 $[\alpha]_D = +22.1$  (*c* 0.997, chloroform)


Source of chirality: D-mannitol

Absolute configuration: 1*S*,2*R*Diethyl (1*R*,2*R*)-3-acetamido-1,2-dihydroxypropylphosphonate

E.e. = 100%

 $[\alpha]_D = +19.0$  (*c* 0.98, chloroform)

Source of chirality: D-mannitol


Absolute configuration: 1*R*,2*R*Diethyl (1*S*,2*R*)-3-acetamido-1,2-dihydroxypropylphosphonate

E.e. = 100%

 $[\alpha]_D = -77.2$  (*c* 1.01, chloroform)

Source of chirality: D-mannitol

Absolute configuration: 1*S*,2*R*




(-)-2,2-Dimethyl-1,3-diphenyl-1,3-propanediol

Ee &gt;99% (by chiral HPLC)

 $[\alpha]_D^{25} = -8.0$  ( $c = 1$ , CHCl<sub>3</sub>)

Source of chirality: chemical resolution



Absolute configuration: *R,R*

(+)-2,2-Dimethyl-1,3-diphenyl-1,3-propanediol

Ee &gt;99% (by chiral HPLC)

 $[\alpha]_D^{25} = +8.0$  ( $c = 1$ , CHCl<sub>3</sub>)

Source of chirality: chemical resolution


Absolute configuration: *S,S*

(+)-2,2-Dimethyl-1,3-diphenylpropyl-1,3-bis(camphanate)

De &gt;99% (by NMR)

 $[\alpha]_D^{25} = +1.6$  ( $c = 1$ , CHCl<sub>3</sub>)


Source of chirality: synthesis

(+)-2,2-Dimethyl-1,3-diphenylpropyl-1,3-bis(*N*-carbethoxyprolinate)

De &gt;99% (by NMR)

 $[\alpha]_D^{25} = +15.1$  ( $c = 1$ , CHCl<sub>3</sub>)

Source of chirality: synthesis

 $C_{33}H_{42}N_2O_8$ (-)-2,2-Dimethyl-1,3-diphenylpropyl-1,3-bis(*N*-carbethoxyprolinate)


De &gt;99% (by NMR)

 $[\alpha]_D^{25} = -84.3$  ( $c = 1$ ,  $CHCl_3$ )

Source of chirality: synthesis

Tõnis Kanger,\* Kadri Kriis, Tõnis Pehk, Aleksander-Mati Müürisepp  
and Margus Lopp


Tetrahedron: Asymmetry 13 (2002) 857

 $C_8H_{16}N_2O_2$ (3*S*,3'*S*)-Bimorpholine

E.e. &gt;98%

 $[\alpha]_D^{20} = -29.4$  ( $c = 2.0$ , MeOH)Source of chirality: (*R,R*)-diethyl tartrateAbsolute configuration: 3*S*,3'*S*Tõnis Kanger,\* Kadri Kriis, Tõnis Pehk, Aleksander-Mati Müürisepp  
and Margus Lopp


Tetrahedron: Asymmetry 13 (2002) 857

 $C_8H_{16}N_2O_2$ (2*S*,2'*S*)-Bimorpholine

E.e. &gt;98%


 $[\alpha]_D^{20} = +18.0$  ( $c = 4.89$ , MeOH)Source of chirality: (*R,R*)-diethyl tartrateAbsolute configuration: 2*S*,2'*S*Tõnis Kanger,\* Kadri Kriis, Tõnis Pehk, Aleksander-Mati Müürisepp  
and Margus Lopp

Tetrahedron: Asymmetry 13 (2002) 857

 $C_{18}H_{32}N_2O_6$ (2*S*,2'*S*)-*N,N'*-Di-(*tert*-butoxycarbonyl)bimorpholine

E.e. &gt;98%

 $[\alpha]_D^{21} = +15.3$  ( $c = 1.78$ ,  $CH_2Cl_2$ )Source of chirality: (*R,R*)-diethyl tartrateAbsolute configuration: 2*S*,2'*S*




C<sub>18</sub>H<sub>32</sub>N<sub>2</sub>O<sub>6</sub>  
(3S,3'S)-N,N'-Di-(*tert*-butoxycarbonyl)bimorpholine

E.e. >98%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +86.2 (*c* 5.33, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (*R,R*)-diethyl tartrate

Absolute configuration: 3*S*,3'*S*




C<sub>20</sub>H<sub>40</sub>N<sub>2</sub>O<sub>12</sub>S<sub>2</sub>  
(5*S*,6*S*)-5,6-Bis-(*N*-*tert*-butoxycarbonyl)amino-3,6-dioxadecane 1,10-dimethanesulfonate

[ $\alpha$ ]<sub>D</sub><sup>21</sup> = -7.7 (*c* 3.78, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (*R,R*)-diethyl tartrate

Absolute configuration: 5*S*,6*S*




C<sub>20</sub>H<sub>40</sub>N<sub>2</sub>O<sub>12</sub>S<sub>2</sub>  
(4*S*,5*S*)-4,5-Bis-(*N*-*tert*-butoxycarbonyl)aminomethyl-3,6-dioxaoctane-1,8-dimethanesulfonate

[ $\alpha$ ]<sub>D</sub><sup>19</sup> = -8.5 (*c* 2.67, MeOH)

Source of chirality: (*R,R*)-diethyl tartrate

Absolute configuration: 4*S*,5*S*





C<sub>18</sub>H<sub>36</sub>N<sub>2</sub>O<sub>8</sub>  
(2*S*,3*S*)-Di-*tert*-butyl-2,3-bis[(2'-hydroxy)ethoxy]-1,4-butanedicarbamate

[ $\alpha$ ]<sub>D</sub><sup>19</sup> = -12.1 (*c* 2.22, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (*R,R*)-diethyl tartrate

Absolute configuration: 2*S*,3*S*




(5S,6S)-5,6-Diamino-3,8-dioxadecane-1,10-diol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +11.6 (c 3.78, MeOH)

Source of chirality: (R,R)-diethyl tartrate

Absolute configuration: 5S,6S




(5S,6S)-5,6-Diazido-3,8-dioxadecane-1,10-diol

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -38.4 (c 4.44, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (R,R)-diethyl tartrate

Absolute configuration: 5S,6S




(1S,2S)-1,2-Diazido-1,2-bis-[(2'-benzyloxy)ethoxymethyl]ethane

[ $\alpha$ ]<sub>D</sub><sup>19</sup> = -26.0 (c 5.67, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (R,R)-diethyl tartrate

Absolute configuration: 1S,2S




(1S,2S)-1,2-Bis-[(2'-benzyloxy)ethoxymethyl]ethane 1,2-dimethanesulfonate

[ $\alpha$ ]<sub>D</sub><sup>18</sup> = -14.6 (c 9.56, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (R,R)-diethyl tartrate

Absolute configuration: 1S,2S




C<sub>22</sub>H<sub>30</sub>O<sub>6</sub>

(2S,3S)-1,4-Bis-[{(2'-benzyloxy)ethoxy]butane-2,3-diol}

[ $\alpha$ ]<sub>D</sub><sup>18</sup> = -2.0 (*c* 9.78, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (*R,R*)-diethyl tartrate

Absolute configuration: 2*S*,3*S*




C<sub>25</sub>H<sub>34</sub>O<sub>6</sub>

(4*S*,5*S*)-4,5-Bis-{[(2'-benzyloxy)ethoxymethyl]-2,2-dimethyl-1,3-dioxolane}

[ $\alpha$ ]<sub>D</sub><sup>19</sup> = -3.7 (*c* 6.33, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (*R,R*)-diethyl tartrate

Absolute configuration: 4*S*,5*S*




C<sub>22</sub>H<sub>28</sub>N<sub>6</sub>O<sub>4</sub>

(2*S*,3*S*)-2,3-Bis[{(2'-benzyloxy)ethoxy]-1,4-diazidobutane}

[ $\alpha$ ]<sub>D</sub><sup>21</sup> = +7.6 (*c* 2.73, CH<sub>2</sub>Cl<sub>2</sub>)

Source of chirality: (*R,R*)-diethyl tartrate

Absolute configuration: 2*S*,3*S*



C<sub>8</sub>H<sub>20</sub>N<sub>2</sub>O<sub>4</sub>

(4*S*,5*S*)-4,5-Diaminomethyl-3,6-dioxa-1,8-octanediol


[ $\alpha$ ]<sub>D</sub><sup>19</sup> = -35.3 (*c* 1.89, MeOH)

Source of chirality: (*R,R*)-diethyl tartrate

Absolute configuration: 4*S*,5*S*

Federica Compostella, Laura Franchini,  
Giovanni Battista Giovenzana, Luigi Panza,\* Davide Prosperi  
and Fiamma Ronchetti

*Tetrahedron: Asymmetry* 13 (2002) 867



(2*R*,*S*)-1,2-*O*-Cyclohexylidene-4-octadecyn-1,2,3-triol

D.e. >95%


$[\alpha]_D = +16.9$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: enzymatic acylation

Absolute configuration: 2*R*,3*R*

Federica Compostella, Laura Franchini,  
Giovanni Battista Giovenzana, Luigi Panza,\* Davide Prosperi  
and Fiamma Ronchetti

*Tetrahedron: Asymmetry* 13 (2002) 867



(2*R*,*S*)-3-*O*-Acetyl-1,2-*O*-cyclohexylidene-4-octadecyn-1,2,3-triol

D.e. >95%


$[\alpha]_D = -25.8$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: Mitsunobu inversion

Absolute configuration: 2*R*,3*R*

Federica Compostella, Laura Franchini,  
Giovanni Battista Giovenzana, Luigi Panza,\* Davide Prosperi  
and Fiamma Ronchetti

*Tetrahedron: Asymmetry* 13 (2002) 867



(2*R*,*S*)-1,2-*O*-Cyclohexylidene-4-octadecyn-1,2,3-triol

D.e. >95%


$[\alpha]_D = +20.0$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: enzymatic acylation

Absolute configuration: 2*R*,3*S*

Federica Compostella, Laura Franchini,  
Giovanni Battista Giovenzana, Luigi Panza,\* Davide Prosperi  
and Fiamma Ronchetti

*Tetrahedron: Asymmetry* 13 (2002) 867



(2*R*,*S*)-3-*O*-Acetyl-1,2-*O*-cyclohexylidene-4-octadecyn-1,2,3-triol

D.e. >95%


$[\alpha]_D = +57.5$  (*c* 0.68, CHCl<sub>3</sub>)

Source of chirality: enzymatic acylation

Absolute configuration: 2*R*,3*S*

Federica Compostella, Laura Franchini,  
Giovanni Battista Giovenzana, Luigi Panza,\* Davide Prosperi  
and Fiamma Ronchetti

*Tetrahedron: Asymmetry* 13 (2002) 867



(*2R,3R,4E*)-1,2-*O*-Cyclohexylidene-4-octadecen-1,2,3-triol

D.e. >95%


$[\alpha]_D = -1.0$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: enzymatic acylation

Absolute configuration: 2*R*,3*R*

Federica Compostella, Laura Franchini,  
Giovanni Battista Giovenzana, Luigi Panza,\* Davide Prosperi  
and Fiamma Ronchetti

*Tetrahedron: Asymmetry* 13 (2002) 867



(*2R,3R,4E*)-3-*O*-Benzoyl-1,2-*O*-cyclohexylidene-4-octadecen-1,2,3-triol

D.e. >95%


$[\alpha]_D = +16.7$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: enzymatic acylation

Absolute configuration: 2*R*,3*R*

Federica Compostella, Laura Franchini,  
Giovanni Battista Giovenzana, Luigi Panza,\* Davide Prosperi  
and Fiamma Ronchetti

*Tetrahedron: Asymmetry* 13 (2002) 867



(*2R,3R,4E*)-3-*O*-Benzoyl-2-*O*-chloromethylsulfonyl-1-*O*-thexyldimethylsilyl-4-octadecen-1,2,3-triol

D.e. >95%


$[\alpha]_D = -1.6$  (*c* 1, CHCl<sub>3</sub>)

Source of chirality: enzymatic acylation

Absolute configuration: 2*R*,3*R*

Stanisław Lochyński,\* Bożena Frąckowiak, Tadeusz Librowski,  
Ryszard Czarnecki, Jacek Grochowski, Paweł Serda and  
Marta Pasenkiewicz-Gierula

*Tetrahedron: Asymmetry* 13 (2002) 873



(*1S,3R,6R,2'R*)-(-)-4-[2',3'-Dihydroxy)propoxyimino]-*cis*-carane

E.e. >97%



$[\alpha]_D^{20} = -50.7$  (*c* = 2.5, CHCl<sub>3</sub>)

Source of chirality: hydrolytic kinetic resolution

Absolute configuration: 1*S*,3*R*,6*R*,2*R*

Stanisław Lochyński,\* Bożena Frąckowiak, Tadeusz Librowski,  
Ryszard Czarnecki, Jacek Grochowski, Paweł Serda and  
Marta Pasenkiewicz-Gierula

*Tetrahedron: Asymmetry* 13 (2002) 873



(1*S*,3*R*,6*R*,2'*S*)(*-*)-4-[2',3'-Dihydroxy)propoxyimino]-*cis*-carane

E.e. >97%



[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -28.3 (*c* = 2.0, CHCl<sub>3</sub>)

Source of chirality: hydrolytic kinetic resolution

Absolute configuration: 1*S*,3*R*,6*R*,2'*S*

Stanisław Lochyński,\* Bożena Frąckowiak, Tadeusz Librowski,  
Ryszard Czarnecki, Jacek Grochowski, Paweł Serda and  
Marta Pasenkiewicz-Gierula

*Tetrahedron: Asymmetry* 13 (2002) 873



(1*S*,3*R*,6*R*,2'*R*)(*-*)-4-[2',3'-Epoxy)propoxyimino]-*cis*-carane

E.e. >99%



[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -34.6 (*c* = 2.0, CHCl<sub>3</sub>)

Source of chirality: hydrolytic kinetic resolution

Absolute configuration: 1*S*,3*R*,6*R*,2'*R*

Stanisław Lochyński,\* Bożena Frąckowiak, Tadeusz Librowski,  
Ryszard Czarnecki, Jacek Grochowski, Paweł Serda and  
Marta Pasenkiewicz-Gierula

*Tetrahedron: Asymmetry* 13 (2002) 873



(1*S*,3*R*,6*R*,2'*S*)(*-*)-4-[2',3'-Epoxy)propoxyimino]-*cis*-carane

E.e. >97%


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -53.6 (*c* = 2.0, CHCl<sub>3</sub>)

Source of chirality: hydrolytic kinetic resolution or  
Mitsunobu reaction

Absolute configuration: 1*S*,3*R*,6*R*,2'*S*

Stanisław Lochyński,\* Bożena Frąckowiak, Tadeusz Librowski,  
Ryszard Czarnecki, Jacek Grochowski, Paweł Serda and  
Marta Pasenkiewicz-Gierula

*Tetrahedron: Asymmetry* 13 (2002) 873



(1*S*,3*R*,6*R*,2'*R*)(*-*)-4-[2'-Hydroxy-3'-(N-isopropylamino)propoxyimino]-*cis*-carane hydrochloride


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -33.7 (*c* = 5.0, EtOH)

Source of chirality: hydrolytic kinetic resolution

Absolute configuration: 1*S*,3*R*,6*R*,2'*R*

Stanisław Lochyński,\* Bożena Frąckowiak, Tadeusz Librowski,  
Ryszard Czarnecki, Jacek Grochowski, Paweł Serda and  
Marta Pasenkiewicz-Gierula

*Tetrahedron: Asymmetry* 13 (2002) 873



C<sub>16</sub>H<sub>30</sub>N<sub>2</sub>O<sub>2</sub>·HCl

(1S,3R,6R,2'S)-(-)-4-[2'-Hydroxy-3'-(N-isopropylamino)propoxyimino]-*cis*-carane hydrochloride


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -7.2 (*c* = 5.0, EtOH)

Source of chirality: hydrolytic kinetic resolution

Absolute configuration: 1S,3R,6R,2'S

Nicolas Baldovini and Guy Solladié\*

*Tetrahedron: Asymmetry* 13 (2002) 885



C<sub>15</sub>H<sub>26</sub>O<sub>2</sub>

(1S,2S,3R)-(4-Methyl-3-pentenyl)-2,3-bis(hydroxymethyl)bicyclo[2.2.1]heptane

E.e. >96%


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = +26 (*c* = 1.18, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (1S,2S,3R)

Nicolas Baldovini and Guy Solladié\*

*Tetrahedron: Asymmetry* 13 (2002) 885



C<sub>17</sub>H<sub>30</sub>O<sub>6</sub>S<sub>2</sub>

(1S,2S,3R)-2-(4-Methyl-3-pentenyl)bicyclo[2.2.1]heptane-2,3-bis(methylmethane sulfonate)

E.e. >96%


[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -13 (*c* = 2.18, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis

Absolute configuration: (1S,2S,3R)

Nicolas Baldovini and Guy Solladié\*

*Tetrahedron: Asymmetry* 13 (2002) 885



C<sub>16</sub>H<sub>26</sub>O<sub>3</sub>S


(1S,2S)-3-Methylidene-2-(4-methyl-3-pentenyl)bicyclo[2.2.1]heptane-2-methyl methanesulfonate

E.e. >96%

[ $\alpha$ ]<sub>D</sub><sup>25</sup> = -64 (*c* = 1.35, CHCl<sub>3</sub>)

Source of chirality: asymmetric synthesis


Absolute configuration: 1S,2S

Bis-[(1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl] 2-(4-methyl-3-pentenyl)maleate

E.e. &gt;99%

 $[\alpha]_D^{25} = -94$  ( $c = 1.19$ ,  $\text{CHCl}_3$ )


Source of chirality: (-)-menthol

Bis-[(1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl] (1*S*,2*S*,3*R*)-2-(4-methyl-3-pentenyl)bicyclo[2.2.1]hept-5-ene-2,3-dicarboxylate

D.e. &gt;96%

 $[\alpha]_D^{25} = -114$  ( $c = 1.15$ ,  $\text{CHCl}_3$ )


Source of chirality: (-)-menthol


Absolute configuration: (1*S*,2*S*,3*R*)(1*S*,2*S*,3*R*)-(4-Methyl-3-pentenyl)-2,3-bis(hydroxymethyl)bicyclo[2.2.1]hept-5-ene

E.e. &gt;96%

 $[\alpha]_D^{25} = +22$  ( $c = 1.12$ ,  $\text{CHCl}_3$ )

Source of chirality: asymmetric synthesis

Absolute configuration: (1*S*,2*S*,3*R*)(1*S*)-1-(2,2',6,6'-Tetramethoxy-1,1'-biphenyl-3-yl)ethanolE.e.=95% (by  $^1\text{H}$  NMR spectrum in the presence of  $\text{Eu}(\text{hfc})_3$  of the corresponding acetate) $[\alpha]_D = -13.7$  ( $c = 0.96$ ,  $\text{CHCl}_3$ )Source of chirality: (*R*)-CBS-Me-catalysed asymmetric reductionAbsolute configuration: *S*




(1*S*)-2,2'-Dimethyl-1-(2,2',6,6'-tetramethoxy-1,1'-biphenyl-3-yl)propan-1-ol

E.e.=93% (by chiral HPLC)

$[\alpha]_D = -18.4$  (*c* 1.68, CHCl<sub>3</sub>)

Source of chirality: (*R*)-CBS-Me-catalysed asymmetric reduction

Absolute configuration: *S*




(a*R*,1*S*,1'*S*)-1,1'-(2,2',6,6'-Tetramethoxy-1,1'-biphenyl-3,3'-diyl) diethanol

E.e.=95% (by chiral HPLC)

$[\alpha]_D = -14.8$  (*c* 0.75, CHCl<sub>3</sub>)

Source of chirality: (*R*)-CBS-Me-catalysed asymmetric reduction

Absolute configuration: a*R,S,S*




(a*S*,1*S*,1'*S*)-1,1'-(2,2',6,6'-Tetramethoxy-1,1'-biphenyl-3,3'-diyl) diethanol

E.e.>98% (by chiral HPLC)

$[\alpha]_D = -23.4$  (*c* 0.43, CHCl<sub>3</sub>)

Source of chirality: (*R*)-CBS-Me-catalysed asymmetric reduction

Absolute configuration: a*S,S,S*



(a*S*,1*R*,1'*S*)-1,1'-(2,2',6,6'-Tetramethoxy-1,1'-biphenyl-3,3'-diyl) diethanol

E.e.=80% (by chiral HPLC)


$[\alpha]_D = -5.2$  (*c* 0.25, CHCl<sub>3</sub>)

Source of chirality: (*R*)-CBS-Me-catalysed asymmetric reduction

Absolute configuration: a*S,R,S*

Giovanna Delogu,\* Davide Fabbri, Cristina de Candia, Angela Patti\*  
and Sonia Pedotti

*Tetrahedron: Asymmetry* 13 (2002) 891



(aS)-1,1'-(2,2',6,6'-Tetramethoxy-1,1'-biphenyl-3,3'-diyl)diethanone

E.e. >98% (by chiral HPLC)


$[\alpha]_D = +35.6$  (*c* 0.72,  $C_6H_6$ )

Source of chirality: oxidation of (aS,1S,1'S)-1,1'-(2,2',6,6'-tetramethoxy-1,1'-biphenyl-3,3'-diyl)diethanol

Absolute configuration: aS

Agnese Abate, Elisabetta Brenna,\* Claudia Dei Negri,  
Claudio Fuganti and Stefano Serra

*Tetrahedron: Asymmetry* 13 (2002) 899



(-)2-(3-Isopropylphenyl)propanol acetate

E.e. >99%


$[\alpha]_D^{20} = -10.8$  (*c* 1.09,  $CHCl_3$ )

Source of chirality: enzymatic resolution

Absolute configuration: 2S

Agnese Abate, Elisabetta Brenna,\* Claudia Dei Negri,  
Claudio Fuganti and Stefano Serra

*Tetrahedron: Asymmetry* 13 (2002) 899



(+)-3-(3-Isopropylphenyl)butanol

E.e. = 97%


$[\alpha]_D^{20} = +16.6$  (*c* 1.25,  $CHCl_3$ )

Source of chirality: enzymatic synthesis

Absolute configuration: 3S

Agnese Abate, Elisabetta Brenna,\* Claudia Dei Negri,  
Claudio Fuganti and Stefano Serra

*Tetrahedron: Asymmetry* 13 (2002) 899




(+)-2-(3-Isopropylphenyl)propanol

E.e. >99%

$[\alpha]_D^{20} = +10.8$  (*c* 1.54,  $CHCl_3$ )

Source of chirality: enzymatic resolution

Absolute configuration: 2R




C<sub>13</sub>H<sub>17</sub>N  
(-) -3-(3-Isopropylphenyl)butyronitrile

E.e. >99%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = -2.9 (c 1.7, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3S



C<sub>13</sub>H<sub>18</sub>O  
(+)-Florhydral®(+)-3-(3-Isopropylphenyl)butanal

E.e. >99%

[ $\alpha$ ]<sub>D</sub><sup>20</sup> = +30.7 (c 1.39, CHCl<sub>3</sub>)

Source of chirality: enzymatic resolution

Absolute configuration: 3S